The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Establishing a neoadjuvant platform for developing targeted agents: Degarelix prior to prostatectomy for patients with intermediate- and high-risk prostate cancer.
Karim A. Touijer
No relevant relationships to disclose
Yingbei Chen
No relevant relationships to disclose
Brett Stewart Carver
No relevant relationships to disclose
Jonathan A. Coleman
No relevant relationships to disclose
Vincent Paul Laudone
No relevant relationships to disclose
Melanie Hullings
No relevant relationships to disclose
Samantha Spenser Ehrlich
No relevant relationships to disclose
Mia DeNunzio
No relevant relationships to disclose
Victor E. Reuter
No relevant relationships to disclose
James Andrew Eastham
No relevant relationships to disclose
Daniel Costin Danila
No relevant relationships to disclose
Susan F. Slovin
No relevant relationships to disclose
Michael J. Morris
No relevant relationships to disclose
Yu Chen
No relevant relationships to disclose
Peter T. Scardino
No relevant relationships to disclose
Howard I. Scher
No relevant relationships to disclose
Dana E. Rathkopf
No relevant relationships to disclose